These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 15801941)

  • 1. Ineffectiveness of lipid-lowering therapy in primary care.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Travier N; Yin D; Alemao E; de Pouvourville G
    Br J Clin Pharmacol; 2005 Apr; 59(4):456-63. PubMed ID: 15801941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Inadequate management of dyslipidaemic patients in France. Results of the Odyssée study].
    Ferrières J; Elbaz M; Maupas E; Carriè D; Puel J
    Arch Mal Coeur Vaiss; 2004 Mar; 97(3):187-93. PubMed ID: 15106741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to prescription guidelines and achievement of treatment goals among persons with coronary heart disease in Tromsø 7.
    Pedersen E; Garcia BH; Halvorsen KH; Eggen AE; Schirmer H; Waaseth M
    BMC Cardiovasc Disord; 2021 Jan; 21(1):44. PubMed ID: 33478404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG).
    Ramjeeth A; Butkow N; Raal FJ; Maholwana-Mokgatlhe M
    Cardiovasc J Afr; 2008; 19(2):88-94. PubMed ID: 18516354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Attainment of low-density lipoprotein cholesterol target in the French general population according to levels of cardiovascular risk: Insights from the MONA LISA study.
    Bongard V; Dallongeville J; Arveiler D; Ruidavets JB; Amouyel P; Wagner A; Ferrières J
    Arch Cardiovasc Dis; 2013 Feb; 106(2):93-102. PubMed ID: 23527913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study.
    García Ruiz FJ; Marín Ibáñez A; Pérez-Jiménez F; Pintó X; Nocea G; Ahumada C; Alemao E; Yin D;
    Pharmacoeconomics; 2004; 22 Suppl 3():1-12. PubMed ID: 15669149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescription of lipid-lowering medications for patients with type 2 diabetes mellitus and risk-associated LDL cholesterol: a nationwide study of guideline adherence from the Swedish National Diabetes Register.
    Karlsson SA; Franzén S; Svensson AM; Miftaraj M; Eliasson B; Andersson Sundell K
    BMC Health Serv Res; 2018 Nov; 18(1):900. PubMed ID: 30486824
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
    Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
    JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term achievement of the therapeutic objectives of lipid-lowering agents in primary prevention patients and cardiovascular outcomes: an observational study.
    Van Ganse E; Souchet T; Laforest L; Moulin P; Bertrand M; Le Jeunne P; Chretin S; Yin D; Alemao E; de Pouvourville G
    Atherosclerosis; 2006 Mar; 185(1):58-64. PubMed ID: 16038912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipid levels and the use of lipid-lowering agents in England and Scotland.
    Primatesta P; Poulter NR
    Eur J Cardiovasc Prev Rehabil; 2004 Dec; 11(6):484-8. PubMed ID: 15580059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipid disorders: justification of methods and goals of treatment.
    Braunstein JB; Cheng A; Cohn G; Aggarwal M; Nass CM; Blumenthal RS
    Chest; 2001 Sep; 120(3):979-88. PubMed ID: 11555537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
    LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
    Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The undertreatment of LDL-cholesterol: addressing the challenge.
    Pearson TA
    Int J Cardiol; 2000 Jun; 74 Suppl 1():S23-8. PubMed ID: 10856770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey.
    Kones R
    Drug Des Devel Ther; 2011; 5():325-80. PubMed ID: 21792295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns.
    Ruof J; Klein G; März W; Wollschläger H; Neiss A; Wehling M
    Prev Med; 2002 Jul; 35(1):48-53. PubMed ID: 12079440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL)].
    Föger B; Patsch JR
    Wien Klin Wochenschr; 2011 Jan; 123(1-2):21-7. PubMed ID: 21165704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal control of lipid levels: results from the non-interventional Centralized Pan-Russian Survey of the Undertreatment of Hypercholesterolemia II (CEPHEUS II).
    Boytsov S; Logunova N; Khomitskaya Y;
    Cardiovasc Diabetol; 2017 Dec; 16(1):158. PubMed ID: 29246151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patterns and effectiveness of lipid-lowering therapies in a managed care environment.
    Meyer JW; Schultz JS; O'Donnell JC; Patel PA; Sasane RM
    Value Health; 2005; 8(5):601-12. PubMed ID: 16176498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extent of control of cardiovascular risk factors and adherence to recommended therapies in US multiethnic adults with coronary heart disease: from a 2005-2006 national survey.
    Vulic D; Lee BT; Dede J; Lopez VA; Wong ND
    Am J Cardiovasc Drugs; 2010; 10(2):109-14. PubMed ID: 20334448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary prevention of coronary artery disease in contemporary clinical practice.
    Jankowski P; Czarnecka D; Wolfshaut-Wolak R; Łysek R; Łukaszewska A; Bogacki P; Grodecki J; Mirek-Bryniarska E; Nessler J; Podolec P; Kawecka-Jaszcz K; Pająk A
    Cardiol J; 2015; 22(2):219-26. PubMed ID: 25299500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.